Table 5 Differences in AR marker level between the studied prostatic carcinoma patients regarding clinic-pathological data
Variable (N = 100) | Marker | Chi-square test | P value | |
|---|---|---|---|---|
Androgen receptor expression (N = 100) | ||||
Negative (N = 4) N% | Positive (N = 96) N% | |||
Age groups (years) | ||||
 ≤ 65 (64) | 2 3.1% | 62 96.9% | 0.177 | 0.674 |
 > 65 (36) | 2 5.6% | 34 94.4% | ||
pT | ||||
T2 (56) | 4 7.1% | 52 92.9% | 1.637 | 0.201 |
T3 (44) | 0 0.0% | 44 100.0% | ||
N | ||||
Positive (42) | 4 9.5% | 38 90.5% | 2.877 | .090 |
Negative (58) | 0 0.0% | 58 100.0% | ||
Stage | ||||
I (12) | 4 33.3% | 8 66.7% | 7.44 | 0.01 (S) |
II (24) | 0 0.0% | 24 100.0% | ||
III (48) | 0 0.0% | 48 100.0 | ||
IV (16) | 0 0.0% | 16 100.0% | ||
Gleason grade group | ||||
1 (10) | 4 40.0% | 6 60.0% | 9.415 | 0.03 (S) |
2 (4) | 0 0.0% | 4 100.0% | ||
3 (10) | 0 0.0% | 10 100.0% | ||
4 (38) | 0 0.0% | 38 100.0% | ||
5 (38) | 0 0.0% | 38 100.0% | ||
PSA level | ||||
 < 4 ng/ml (6) | 0 0.0% | 6 100.0% | 1.04 | 1.0 |
4-10Â ng/ml (56) | 2 3.6% | 54 96.4% | ||
 > 10 ng/ml (38) | 2 5.3% | 36 94.7% | ||
Capsular invasion | ||||
Present (36) | 4 11.1% | 32 88.9% | 3.704 | 0.05 |
Absent (64) | 0 0.0% | 64 100.0% | ||
LVI | ||||
Present (34) | 4 11.8% | 30 88.2% | 4.04 | 0.111 |
Absent (66) | 0 0.0% | 66 100.0% | ||
Perineural invasion | ||||
Present (52) | 2 3.8% | 50 96.2% | .003 | 0.954 |
Absent (48) | 2 4.2% | 46 95.8% | ||